• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Exploring the role of urine drug screening in opioid agonist therapy.探索尿液药物筛查在阿片类激动剂治疗中的作用。
Med J Aust. 2025 May 5;222(8):381-383. doi: 10.5694/mja2.52628. Epub 2025 Mar 5.
2
Engagement in Harm Reduction Strategies After Suspected Fentanyl Contamination Among Opioid-Dependent Individuals.疑似芬太尼污染后阿片类药物依赖者采取减少伤害策略的参与情况。
J Community Health. 2021 Apr;46(2):349-357. doi: 10.1007/s10900-020-00928-3. Epub 2020 Sep 30.
3
Modelling integrated antiretroviral treatment and harm reduction services on HIV and overdose among people who inject drugs in Tijuana, Mexico.在墨西哥提华纳，对注射吸毒者中的艾滋病毒和过量使用药物进行综合抗逆转录病毒治疗和减少伤害服务建模。
J Int AIDS Soc. 2020 Jun;23 Suppl 1(Suppl 1):e25493. doi: 10.1002/jia2.25493.
4
Optimum methadone compliance testing: an evidence-based analysis.最佳美沙酮依从性检测：基于证据的分析。
Ont Health Technol Assess Ser. 2006;6(21):1-54. Epub 2006 Dec 1.
5
Large Variation in Provincial Guidelines for Urine Drug Screening during Opioid Agonist Treatment in Canada.加拿大阿片类激动剂治疗期间尿液药物筛查省级指南存在很大差异。
Can J Addict. 2018 Jun;9(2):6-9. doi: 10.1097/CXA.0000000000000015.
6
Evaluating interventions to facilitate opioid agonist treatment access among people who inject drugs in Toronto, Ontario during COVID-19 pandemic restrictions.评估在 COVID-19 大流行限制期间，在安大略省多伦多为注射吸毒者提供阿片类激动剂治疗的干预措施。
Int J Drug Policy. 2022 Jun;104:103680. doi: 10.1016/j.drugpo.2022.103680. Epub 2022 Apr 13.
7
Alcohol Screening among Opioid Agonist Patients in a Primary Care Clinic and an Opioid Treatment Program.在一家初级保健诊所和一个阿片类药物治疗项目中对阿片类激动剂患者进行酒精筛查。
J Psychoactive Drugs. 2015 Jan-Mar;47(1):65-70. doi: 10.1080/02791072.2014.991859.
8
Expanding harm reduction to include fentanyl urine testing: results from a pilot in rural British Columbia.扩大减少伤害的范围，包括芬太尼尿液检测：不列颠哥伦比亚省农村地区试点的结果。
Harm Reduct J. 2018 Apr 6;15(1):19. doi: 10.1186/s12954-018-0224-z.
9
Harm Reduction Coverage and Hepatitis C Incidence: Findings From a Cohort of People Who Inject Drugs.减少伤害覆盖范围与丙型肝炎发病率：来自注射毒品人群队列的研究结果
Am J Prev Med. 2020 Jun;58(6):845-853. doi: 10.1016/j.amepre.2020.01.024.
10
An individual-based dynamic model to assess interventions to mitigate opioid overdose risk.基于个体的动态模型，用于评估减轻阿片类药物过量风险的干预措施。
Harm Reduct J. 2024 Aug 13;21(1):146. doi: 10.1186/s12954-024-01069-9.

本文引用的文献

1
Prescription drug monitoring program in Australia: a qualitative study of stakeholders' experiences and perceptions of a state-wide implementation.澳大利亚的处方药物监测项目：对利益相关者在全州范围内实施该项目的经验和看法的定性研究。
BMC Health Serv Res. 2024 Sep 29;24(1):1147. doi: 10.1186/s12913-024-11614-8.
2
Association of random and observed urine drug screening with long-term retention in opioid treatment programs.随机和观察性尿液药物筛查与阿片类药物治疗项目长期保留的关联。
Drug Alcohol Depend. 2024 Feb 1;255:111067. doi: 10.1016/j.drugalcdep.2023.111067. Epub 2023 Dec 24.
3
Deimplementation in the provision of opioid agonist treatment to achieve equity of care for people engaged in treatment: a qualitative study.在提供阿片类激动剂治疗以实现接受治疗者获得公平照护方面的去实施化：一项定性研究。
Implement Sci. 2023 Jun 9;18(1):22. doi: 10.1186/s13012-023-01281-4.
4
Agreement between self-reported illicit drug use and biological samples: a systematic review and meta-analysis.自我报告的非法药物使用与生物样本之间的一致性：系统评价和荟萃分析。
Addiction. 2023 Sep;118(9):1624-1648. doi: 10.1111/add.16200. Epub 2023 May 4.
5
Should I Stay or Should I Go? A Qualitative Exploration of Stigma and Other Factors Influencing Opioid Agonist Treatment Journeys.我该留下还是离开？定性探讨影响阿片类激动剂治疗旅程的污名化和其他因素。
Int J Environ Res Public Health. 2023 Jan 14;20(2):1526. doi: 10.3390/ijerph20021526.
6
Evaluating the association between urine drug screening frequency and retention in opioid agonist treatment in Ontario, Canada: a retrospective cohort study.评估加拿大安大略省尿药物筛查频率与阿片类激动剂治疗保留率之间的关联：一项回顾性队列研究。
BMJ Open. 2022 Oct 12;12(10):e060857. doi: 10.1136/bmjopen-2022-060857.
7
Evaluation of adherence monitoring in buprenorphine treatment: A pilot study using timed drug assays to determine accuracy of testing.评估丁丙诺啡治疗中的药物依从性监测：一项使用时间药物检测来确定检测准确性的试点研究。
Br J Clin Pharmacol. 2023 Jul;89(7):1938-1947. doi: 10.1111/bcp.15318. Epub 2022 Mar 31.
8
Opioid agonist treatment and patient outcomes during the COVID-19 pandemic in south east Sydney, Australia.澳大利亚悉尼东南部在 COVID-19 大流行期间阿片类激动剂治疗和患者结局。
Drug Alcohol Rev. 2022 Jul;41(5):1009-1019. doi: 10.1111/dar.13382. Epub 2021 Sep 14.
9
"It's like 'liquid handcuffs": The effects of take-home dosing policies on Methadone Maintenance Treatment (MMT) patients' lives.“就像‘液体手铐’：美沙酮维持治疗（MMT）患者生活中的带药政策影响。”
Harm Reduct J. 2021 Aug 14;18(1):88. doi: 10.1186/s12954-021-00535-y.
10
Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence: A Systematic Review and Meta-analysis.阿片类激动剂治疗与阿片类药物依赖患者全因死亡率及特定死因的相关性：系统评价和荟萃分析。
JAMA Psychiatry. 2021 Sep 1;78(9):979-993. doi: 10.1001/jamapsychiatry.2021.0976.

Exploring the role of urine drug screening in opioid agonist therapy.

作者信息

FitzGerald Grace, Crawford Sione, Dunlop Adrian J, Cook Jon, Membrey Dean, MacCartney Paul, Naren Thileepan

机构信息

Western Health, Melbourne, VIC.

Harm Reduction Victoria, Melbourne, VIC.

出版信息

Med J Aust. 2025 May 5;222(8):381-383. doi: 10.5694/mja2.52628. Epub 2025 Mar 5.

DOI:10.5694/mja2.52628
PMID:40043364
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12050249/
Abstract
摘要